Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts t

1. Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016

2. The Dysmenorrhea Therapeutics Market is Forecast to Show Slow Growth to 2016 The global dysmenorrhea therapeutics market was valued at $1.7 billion in 2009. It is expected to grow to $2.3 billion at a compound annual growth rate (CAGR) of 3.9% by 2016. This slow growth is primarily attributed to a lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. The current competitive landscape consists of only generics and off-label therapies, none of which have a dominant position. The current emphasis has been on treating the symptoms of the disease without providing an absolute cure. For more information please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Dysmenorrhea-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Current Treatment Options are Moderately Successful in Meeting Market Demand GlobalData has analyzed the current market landscape and found it to be weak. The market is currently dominated by NSAIDs (generics). NSAIDs are the most commonly used treatments for dysmenorrhea. NSAIDs decrease menstrual pain by decreasing intrauterine pressure and lowering PGF2alpha levels in menstrual fluid. Gastrointestinal (GI) upset is the most common adverse effect associated with NSAIDs, and patients receiving these medications are monitored for more serious adverse effects, including GI bleeding and renal dysfunction. COX-2 specific inhibitors have also proven effective in relieving menstrual pain. Their selectivity reduces the GI symptoms caused by inhibition of the COX-1 receptor. However, recent clinical trials have raised concerns over their cardiovascular safety profiles. As a result, some of these agents are no longer available. Oral contraceptives are also prescribed for primary dysmenorrhea. However, these drugs are not approved by the FDA for the treatment of dysmenorrhea. They are effective because of their ability to inhibit ovulation.

3. Low Treatment Seeking Rate is a Major Barrier for the Dysmenorrhea Market The treatment seeking population for dysmenorrhea in the seven major markets was small. Increasing awareness regarding the disease complications and etiology are major factors influencing the growth of the treatment seeking population. There is a huge gap between the diseased and treatment seeking populations for dysmenorrhea. This is primarily attributed to the nature of the disease. Even though people are diagnosed, due to its nature, the medications used to treat dysmenorrhea and their potentially serious side effects, and the lack of a cure, many patients seek other ways of treating the disease. Some of the alternative approaches that have been suggested include special diets, nutritional supplements and homeopathy. OTC (Over The Counter) medications like Acetameniphen or Ibuprofen are also used by women who experience discomfort during menstruation. For more information please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Dysmenorrhea-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Weak Pipeline Candidates are Not Likely to Improve the Dysmenorrhea Treatment Paradigm The dysmenorrhea developmental pipeline is substantially weak with about 15 products in various phases of clinical development. The launch of new products will not significantly alter the dysmenorrhea market. These newly launched products do not offer superior efficacy to the currently marketed generic products. This implies that patients do not see differences in terms of disease modification. Most of the molecules in clinical development are me-too. There are eight me-too molecules over all the phases of clinical development. These molecules are a mixture of prostaglandin synthetase inhibitors and COX-2 inhibitors. Therefore these newly launched products are not likely to capture major market shares or see heavy price premiums.

4. GlobalData, the industry analysis specialist, has released its latest research, “Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016” which provides key data, information and analysis on the dysmenorrhea market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecasts for seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with dysmenorrhea, competitive assessment, product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, implications for the future market competition, and the key players of the dysmenorrhea market. For more information please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Dysmenorrhea-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare Or visit our report store: http://www.globaldata.com/reportstore Contact Information: Rajesh Gunnam rgunnam@globaldata.com +914066166782